Blog Viewer

Neuroimaging Findings in Sepsis-Induced Brain Dysfunction: Association with Clinical and Laboratory Findings

By Currents Editor posted 02-11-2019 14:03

  

By Günseli Orhun, Figen Esen, Perihan Ergin Özcan, Serra Sencer, Başar Bilgiç, Canan Ulusoy, Handan Noyan, Melike Küçükerden, Achmet Ali, Mehmet Barburoğlu, Erdem Tüzün

Background

Incidence and patterns of brain lesions of sepsis-induced brain dysfunction (SIBD) have been well defined. Our objective was to investigate the associations between neuroimaging features of SIBD patients and well-known neuroinflammation and neurodegeneration factors.

Methods

In this prospective observational study, 93 SIBD patients (45 men, 48 women; 50.6 ± 12.7 years old) were enrolled. Patients underwent a neurological examination and brain magnetic resonance imaging (MRI). Severity-of-disease scoring systems (APACHE II, SOFA, and SAPS II) and neurological outcome scoring system (GOSE) were used. Also, serum levels of a panel of mediators [IL-1β, IL-6, IL-8, IL-10, IL-12, IL-17, IFN-γ, TNF-α, complement factor Bb, C4d, C5a, iC3b, amyloid-β peptides, total tau, phosphorylated tau (p-tau), S100b, neuron-specific enolase] were measured by ELISA. Voxel-based morphometry (VBM) was employed to available patients for assessment of neuronal loss pattern in SIBD.

Results

MRI of SIBD patients were normal (n = 27, 29%) or showed brain lesions (n = 51, 54.9%) or brain atrophy (n = 15, 16.1%). VBM analysis showed neuronal loss in the insula, cingulate cortex, frontal lobe, precuneus, and thalamus. Patients with abnormal MRI findings had worse APACHE II, SOFA, GOSE scores, increased prevalence of delirium and mortality. Presence of MRI lesions was associated with reduced C5a and iC3b levels and brain atrophy was associated with increased p-tau levels. Regression analysis identified an association between C5a levels and presence of lesion on MRI and p-tau levels and the presence of atrophy on MRI.

Conclusions

Neuronal loss predominantly occurs in limbic and visceral pain perception regions of SIBD patients. Complement breakdown products and p-tau stand out as adverse neuroimaging outcome markers for SIBD.

Read more

#NCJ

FURTHER READING
By: (from left to right) Sydney Moseley, MD, Hussein Alshammari, MD, Scott Woolf, DO, Fawaz Al-Mufti, MD 1 1 Department of Neurology and Neurosurgery, Westchester Medical Center at New York Medical College The authors have no actual or potential conflict of interest in relation to ...
 By:  Danielle Marut, PharmD (left), Jessica Traeger, PharmD, BCCCP (right) The use of oral factor Xa inhibitors, including rivaroxaban and apixaban, has increased over the last several years. Historically, strategies for the treatment of bleeding patients taking these agents included supportive ...
By Bnar Shawki, MD, MBChB, F.I.C.M.S, FIPP, Head of Anesthesia Department in RozhHalat Emergency Hospital, Erbil, Iraq (left); Firas Abdulmajeed, MBChB, Assistant Professor of Critical Care Medicine and Neurology, University of Pittsburgh, USA (right) The population of Iraq is 37,203,000, according ...